Next Article in Journal
The Bacterial Phytoene Desaturase-Encoding Gene (CRTI) is an Efficient Selectable Marker for the Genetic Transformation of Eukaryotic Microalgae
Next Article in Special Issue
Delta-Tocotrienol Modulates Glutamine Dependence by Inhibiting ASCT2 and LAT1 Transporters in Non-Small Cell Lung Cancer (NSCLC) Cells: A Metabolomic Approach
Previous Article in Journal
Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma
Previous Article in Special Issue
Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers

Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain
Joint Research Unit in Clinical Metabolomics, Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia 46012, Spain
Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia 46009, Spain
Author to whom correspondence should be addressed.
Metabolites 2019, 9(3), 48;
Received: 31 January 2019 / Revised: 1 March 2019 / Accepted: 4 March 2019 / Published: 8 March 2019
(This article belongs to the Special Issue Cancer Metabolomics 2018)
PDF [497 KB, uploaded 8 March 2019]


Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients’ biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa. View Full-Text
Keywords: metabolomics; metabolism; prostate cancer; biomarker; early diagnosis; prognosis metabolomics; metabolism; prostate cancer; biomarker; early diagnosis; prognosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Gómez-Cebrián, N.; Rojas-Benedicto, A.; Albors-Vaquer, A.; López-Guerrero, J.A.; Pineda-Lucena, A.; Puchades-Carrasco, L. Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers. Metabolites 2019, 9, 48.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top